5 key acquisitions drove global connected health leader’s award win
September 24, 2019 –– Boston ResMed has been named the 2019 “Dealmaker of the Year” by Medtech Insight, an award that recognizes the company most adept at advancing its business through investment deals. The award was presented Monday night by Medtech Insight owner Pharma Intelligence, a leading global analyst firm serving the pharmaceutical, medical device, and clinical research industries.
During the entry period (June 2018–June 2019), ResMed announced the acquisition of five companies to advance
its mission of helping keep millions of people healthy and out of the hospital:
“This past year we have helped over 100 million people sleep, breathe, and live higher-quality lives in out-of-hospital healthcare,” said ResMed CEO Mick Farrell. “We’ve grown our business organically and through targeted acquisitions, built out connected device and software ecosystems encompassing over 4.5 billion nights of digital health data. We are transforming these big data into actionable insights for patients, physicians, providers, payers, and communities. Both the cadence and execution of ResMed’s acquisitions drive toward our vision of improving 250 million lives in out-of-hospital healthcare. I’m proud that Pharma Intelligence and Medtech Insight have recognized the ResMed team for this success.” In 2018, Pharma Intelligence recognized ResMed’s AirMini as a 2018 award finalist for “Best Technological Innovation” in the Consumer Devices category.
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower cost for consumers and healthcare systems in more than 120 countries. To learn more, visit
ResMed.com and follow @ResMed.